CN111437245A - Camellia chrysantha L-theanine oral preparation for preventing novel coronavirus pneumonia and preparation method and application thereof - Google Patents
Camellia chrysantha L-theanine oral preparation for preventing novel coronavirus pneumonia and preparation method and application thereof Download PDFInfo
- Publication number
- CN111437245A CN111437245A CN202010238228.XA CN202010238228A CN111437245A CN 111437245 A CN111437245 A CN 111437245A CN 202010238228 A CN202010238228 A CN 202010238228A CN 111437245 A CN111437245 A CN 111437245A
- Authority
- CN
- China
- Prior art keywords
- theanine
- camellia
- parts
- novel coronavirus
- oral preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 title claims abstract description 150
- DATAGRPVKZEWHA-UHFFFAOYSA-N L-gamma-glutamyl-n-ethylamine Natural products CCNC(=O)CCC(N)C(O)=O DATAGRPVKZEWHA-UHFFFAOYSA-N 0.000 title claims abstract description 71
- 238000002360 preparation method Methods 0.000 title claims abstract description 52
- 241000711573 Coronaviridae Species 0.000 title claims abstract description 30
- 206010035664 Pneumonia Diseases 0.000 title claims abstract description 26
- 241001657422 Camellia petelotii Species 0.000 title claims description 33
- 235000018597 common camellia Nutrition 0.000 claims abstract description 48
- 240000001548 Camellia japonica Species 0.000 claims abstract description 43
- 239000000945 filler Substances 0.000 claims abstract description 19
- 235000003599 food sweetener Nutrition 0.000 claims abstract description 19
- 239000000314 lubricant Substances 0.000 claims abstract description 19
- 239000003765 sweetening agent Substances 0.000 claims abstract description 19
- 239000000853 adhesive Substances 0.000 claims abstract description 16
- 230000001070 adhesive effect Effects 0.000 claims abstract description 16
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 16
- 239000000796 flavoring agent Substances 0.000 claims abstract description 16
- 235000013355 food flavoring agent Nutrition 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 36
- 229910000365 copper sulfate Inorganic materials 0.000 claims description 23
- 239000000243 solution Substances 0.000 claims description 23
- 241001328788 Camellia nitidissima Species 0.000 claims description 16
- 239000011259 mixed solution Substances 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 15
- 229920002472 Starch Polymers 0.000 claims description 14
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 14
- 239000008107 starch Substances 0.000 claims description 14
- 235000019698 starch Nutrition 0.000 claims description 14
- 238000001914 filtration Methods 0.000 claims description 11
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 10
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 10
- 239000012535 impurity Substances 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 239000002244 precipitate Substances 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 238000005303 weighing Methods 0.000 claims description 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 9
- 229920000881 Modified starch Polymers 0.000 claims description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 9
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 9
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 239000011347 resin Substances 0.000 claims description 8
- 229920005989 resin Polymers 0.000 claims description 8
- 229920001661 Chitosan Polymers 0.000 claims description 7
- 229920002261 Corn starch Polymers 0.000 claims description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 7
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 claims description 7
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 7
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 7
- 239000008120 corn starch Substances 0.000 claims description 7
- 239000007884 disintegrant Substances 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 235000019359 magnesium stearate Nutrition 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 7
- 229940057838 polyethylene glycol 4000 Drugs 0.000 claims description 7
- 239000002002 slurry Substances 0.000 claims description 7
- 239000011734 sodium Substances 0.000 claims description 7
- 229910052708 sodium Inorganic materials 0.000 claims description 7
- 238000001291 vacuum drying Methods 0.000 claims description 7
- 239000000811 xylitol Substances 0.000 claims description 7
- 235000010447 xylitol Nutrition 0.000 claims description 7
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 7
- 229960002675 xylitol Drugs 0.000 claims description 7
- 235000010489 acacia gum Nutrition 0.000 claims description 6
- 238000001179 sorption measurement Methods 0.000 claims description 6
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 5
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 claims description 5
- 229910001863 barium hydroxide Inorganic materials 0.000 claims description 5
- 229940116318 copper carbonate Drugs 0.000 claims description 5
- 229910001431 copper ion Inorganic materials 0.000 claims description 5
- GEZOTWYUIKXWOA-UHFFFAOYSA-L copper;carbonate Chemical compound [Cu+2].[O-]C([O-])=O GEZOTWYUIKXWOA-UHFFFAOYSA-L 0.000 claims description 5
- 229960000913 crospovidone Drugs 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- 230000007935 neutral effect Effects 0.000 claims description 5
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 5
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 5
- 238000001953 recrystallisation Methods 0.000 claims description 5
- 238000005507 spraying Methods 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 238000005189 flocculation Methods 0.000 claims description 4
- 230000016615 flocculation Effects 0.000 claims description 4
- 238000007873 sieving Methods 0.000 claims description 4
- 238000000967 suction filtration Methods 0.000 claims description 4
- 229940026510 theanine Drugs 0.000 claims description 4
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 claims description 3
- 239000006189 buccal tablet Substances 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 229910000037 hydrogen sulfide Inorganic materials 0.000 claims description 3
- 229940046011 buccal tablet Drugs 0.000 claims description 2
- 239000007789 gas Substances 0.000 claims description 2
- 238000007781 pre-processing Methods 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims 3
- 229920000084 Gum arabic Polymers 0.000 claims 1
- 240000007472 Leucaena leucocephala Species 0.000 claims 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims 1
- 239000000205 acacia gum Substances 0.000 claims 1
- 230000006835 compression Effects 0.000 claims 1
- 238000007906 compression Methods 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- 239000010949 copper Substances 0.000 claims 1
- 244000269722 Thea sinensis Species 0.000 description 19
- 235000006468 Thea sinensis Nutrition 0.000 description 19
- 241000700605 Viruses Species 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 14
- 241001678559 COVID-19 virus Species 0.000 description 9
- 241000209507 Camellia Species 0.000 description 8
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 208000025721 COVID-19 Diseases 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241001122767 Theaceae Species 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000003825 pressing Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- -1 L-theanine copper sulfate Chemical compound 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101150013191 E gene Proteins 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- OMZSGWSJDCOLKM-UHFFFAOYSA-N copper(II) sulfide Chemical compound [S-2].[Cu+2] OMZSGWSJDCOLKM-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
Abstract
The invention provides a golden camellia L-theanine oral preparation for preventing novel coronavirus pneumonia, which comprises the following raw materials, by mass, 15-30 parts of golden camellia L-theanine, 45-65 parts of a filler, 1-2.5 parts of a lubricant, 1-2.5 parts of a disintegrating agent, 1-3 parts of a flavoring agent, 10-30 parts of an adhesive, 10-30 parts of a sweetening agent and the balance of water.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to a golden camellia L-theanine oral preparation for preventing novel coronavirus pneumonia and a preparation method and application thereof.
Background
Camellia nitidissima C.W.Chi belongs to Theaceae and Camellia, and tests of Chinese disease prevention and control center nutrition and food safety show that the Camellia nitidissima is nontoxic and contains multiple effective components with important health care effect on human body, including L-theanine, various vitamins, total saponin, oleanolic acid and multiple trace elements, and has very high medicinal value, especially, the special free amino acid-L-theanine in the Camellia nitidissima, the chemical name of the N-ethyl gamma-L-glutamine, and the content of the N-ethyl gamma-L-glutamine accounts for 0.4-3% of solid matters of the Camellia nitidissima.
Bukowski et al (Bukowski J F, Percival SS L-the human immunity enhancing processes and human gamma-derived immune cells) suggest that certain alkylamines such as theanine can be rapidly recognized by cells directly, thereby activating the immune response of humans, and thus reducing the risk of inducing endogenous influenza, by administering to human volunteers a number of gamma-T immune cells, which are a subset of cells that directly recognize various bacterial, viral and parasitic antigenic components, and thus enhancing the immune system, and thus increasing the resistance of humans against disease by even five-fold invasion of pathogenic microorganisms such as viruses, bacteria and fungi.
However, the application of L-theanine of golden camellia to prevention of novel coronavirus pneumonia has not been reported for a long time.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provide the golden camellia L-theanine oral preparation for preventing the novel coronavirus pneumonia and the preparation method and the application thereof, and the golden camellia L-theanine oral preparation can effectively improve the immunity of a human body and prevent the novel coronavirus pneumonia.
The invention provides a golden camellia L-theanine oral preparation for preventing novel coronavirus pneumonia, which comprises, by mass, 15-30 parts of golden camellia L-theanine, 45-65 parts of a filler, 1-2.5 parts of a lubricant, 1-2.5 parts of a disintegrant, 1-3 parts of a flavoring agent, 10-30 parts of an adhesive, 10-30 parts of a sweetening agent, and the balance of water.
Compared with the prior art, the invention discovers that L-theanine extracted from golden camellia can improve human immunity and can effectively kill novel coronavirus, so that the oral preparation is prepared by taking high-purity L-theanine extracted from golden camellia as a main antiviral active ingredient and compounding auxiliary materials such as a filler, a lubricant, a disintegrating agent, a flavoring agent, an adhesive, a sweetening agent and the like, and provides a new formula for preventing novel coronavirus pneumonia.
Further, the disintegrating agent is any one of sodium carboxymethyl starch, soluble starch and crospovidone; the sweetener is any one of xylitol and mannitol.
Further, the filler is microcrystalline cellulose: pregelatinized starch ═ 1:1, or lactose; the lubricant is any one of magnesium stearate and polyethylene glycol-4000.
Further, the adhesive is any one of Arabic gum and corn starch slurry; the flavoring agent is citric acid.
The invention also provides a preparation method of the golden camellia L-theanine oral preparation for preventing the novel coronavirus pneumonia, which comprises the following steps:
(1) preprocessing golden camellia: selecting leaves or flowers of the golden camellia, cleaning, drying, crushing and sieving to obtain golden camellia tea powder;
(2) the method comprises the steps of (1) extracting L-theanine, weighing camellia chrysantha tea powder, extracting with water at the temperature of 40-80 ℃ for 2-5 hours, filtering, adjusting the pH value of the filtrate to 3.5, adding a chitosan solution into the filtrate for flocculation and impurity removal, decoloring and impurity removal with a nonpolar macroporous adsorption resin, filtering and concentrating the treated solution, adjusting the pH value to be neutral, heating and stirring at the temperature of 60-80 ℃, adding alkaline copper carbonate to obtain a purple precipitate, dissolving the purple precipitate with sulfuric acid to obtain a L-copper sulfate mixed solution, removing the L-copper sulfate mixed solution, removing copper sulfate, performing suction filtration, concentration, vacuum drying and recrystallization to obtain L-theanine;
(3) the preparation method comprises the steps of weighing the camellia chrysantha L-theanine obtained in the step (2), adding a proper amount of water and a disintegrating agent, stirring at 50-60 ℃, adding citric acid, uniformly mixing, adding into an adhesive in a spraying mode, adding a filling agent, a lubricating agent and a sweetening agent, fully mixing, and drying in vacuum to obtain the camellia chrysantha L-theanine oral preparation.
Compared with the prior art, the L-theanine with high purity is separated from the golden camellia, and then is compounded with a proper amount of auxiliary materials such as a filler, a lubricant, a disintegrating agent, a flavoring agent, an adhesive and a sweetening agent to form the oral preparation.
And (3) further comprising a pressing step after the step (3), namely putting the golden camellia L-theanine oral preparation obtained in the step (3) into a rotary tablet press to be pressed into buccal tablets.
Furthermore, the raw materials in the step (3) comprise, by mass, 15-30 parts of camellia chrysantha L-theanine, 45-65 parts of a filler, 1-2.5 parts of a lubricant, 1-2.5 parts of a disintegrating agent, 1-3 parts of a flavoring agent, 10-30 parts of an adhesive, 10-30 parts of a sweetening agent, and the balance water.
Further, the disintegrating agent is any one of sodium carboxymethyl starch, soluble starch and crospovidone; the sweetener is any one of xylitol and mannitol; the filler is microcrystalline cellulose: pregelatinized starch ═ 1:1, or lactose; the lubricant is any one of magnesium stearate and polyethylene glycol-4000; the adhesive is any one of Arabic gum and corn starch slurry; the flavoring agent is citric acid.
Further, in the step (3), the step of removing copper sulfate comprises the steps of introducing excessive hydrogen sulfide gas into the L-theanine copper sulfate mixed solution to remove copper ions, and adding a proper amount of barium hydroxide solution to precipitate sulfate ions, wherein the step of removing copper sulfate is to remove copper ions and sulfate ions in L-theanine and further improve the purity of the obtained camellia nitidissima L-theanine.
Further, in the step (2), the concentration of the chitosan solution is 1%; the nonpolar macroporous resin can be any one of BS-55, BS-65, BS-80, D101, H103, X-5, DM11, HPD-100, D1400, D3250, HP-20, ADS-5 and ADS-8.
The invention also provides application of the camellia chrysantha L-theanine oral preparation for preventing the novel coronavirus pneumonia, and the camellia chrysantha L-theanine oral preparation is applied to preventing the novel coronavirus pneumonia.
For a better understanding and practice, the invention is described in detail below with reference to the accompanying drawings.
Drawings
FIG. 1 is a molecular structure diagram of Camellia nitidissima L-theanine of the present invention.
Detailed Description
The invention provides a golden camellia L-theanine oral preparation (hereinafter, referred to as golden camellia L-theanine oral preparation) for preventing novel coronavirus pneumonia, which comprises the following raw materials, by mass, L-theanine of golden camellia 15-30 parts, a filler 45-65 parts, a lubricant 1-2.5 parts, a disintegrating agent 1-2.5 parts, a flavoring agent 1-3 parts, an adhesive 10-30 parts, a sweetening agent 10-30 parts, and the balance of water.
Wherein the filler is microcrystalline cellulose: pregelatinized starch ═ 1:1, or lactose; the lubricant is any one of magnesium stearate and polyethylene glycol-4000; the disintegrating agent is any one of sodium carboxymethyl starch, soluble starch and crospovidone; the flavoring agent is citric acid; the adhesive is any one of Arabic gum and corn starch slurry; the sweetener is any one of xylitol and mannitol.
Based on the formula, the invention also provides a preparation method of the golden camellia L-theanine oral preparation for preventing the novel coronavirus pneumonia, which comprises the following steps:
(1) camellia chrysantha tea powder is obtained by selecting leaves or flowers of Camellia chrysantha, washing, drying, crushing, sieving with a sieve of 20-40 meshes, Camellia chrysantha tea (such as Camellia sinensis H), Camellia sinensis (such as Camellia sinensis C), Camellia nitidissima (such as Camellia sinensis C), Camellia sinensis C (such as Camellia sinensis C), Camellia nitidissima tea (such as Camellia sinensis C), Camellia sinensis C (such as Camellia sinensis C), Camellia sinensis (such as Camellia sinensis C.g), Camellia sinensis C.1. tea (such as Camellia sinensis C), Camellia sinensis (such as Camellia sinensis C.7. tea, Camellia sinensis C), Camellia sinensis (such as Camellia sinensis C.1. and Camellia sinensis C.1. 1. long.
(2) The method comprises the steps of weighing golden camellia L-theanine, extracting golden camellia tea powder for 2-5 hours by using water at the temperature of 40-80 ℃, filtering, adjusting the pH value of the filtrate to 3.5, adding 1% chitosan solution into the filtrate for flocculation and impurity removal, then carrying out decoloration and impurity removal treatment by using non-polar macroporous adsorption resin, filtering and concentrating the treated solution, adjusting the pH value to be neutral, heating and stirring at the temperature of 60-80 ℃, adding alkaline copper carbonate to obtain a purple precipitate, dissolving the purple precipitate by using sulfuric acid to obtain a L-copper sulfate mixed solution, removing the L-copper sulfate mixed solution for copper sulfate removal treatment, wherein the copper sulfate removal treatment comprises the steps of introducing excessive copper sulfide into the L-copper sulfate mixed solution to remove copper ions, adding a proper amount of barium hydroxide solution to precipitate sulfate ions, carrying out suction filtration, concentration, vacuum drying and recrystallization to obtain the golden camellia L-theanine, and the molecular structure diagram of the golden camellia L-theanine is shown in figure 1.
Wherein the nonpolar macroporous adsorption resin is any one of BS-55, BS-65, BS-80, D101, H103, X-5, DM11, HPD-100, D1400, D3250, HP-20, ADS-5 and ADS-8.
(3) The preparation method comprises the steps of weighing the camellia nitidissima L-theanine obtained in the step (2), adding a proper amount of water and a disintegrating agent, stirring at 50-60 ℃, adding citric acid, uniformly mixing, adding into an adhesive in a spraying mode, adding a filling agent, a lubricating agent and a sweetening agent, fully and uniformly mixing, putting into a rotary tablet press for pressing, and performing vacuum drying to obtain the camellia nitidissima L-theanine buccal tablet.
The present invention is described in detail below by way of examples 1 and 2.
Example 1
(1) The golden Camellia pretreatment is that golden Camellia leaves are selected, optimized according to Chinese pharmacopoeia (2015), washed, dried, crushed into powder and sieved by a 20-mesh sieve to obtain the sieved golden Camellia powder, wherein the golden Camellia is the concave vein golden Camellia (Camellia impressnervis Chang et S.Y. L iang).
(2) L-theanine is extracted by weighing 100g of camellia chrysantha tea powder, extracting the camellia chrysantha tea powder for 3 hours by using 6 times of 60 ℃ water, filtering the camellia chrysantha tea powder, adjusting the pH value of the filtrate to 3.5 by using hydrochloric acid, adding 1% chitosan solution into the filtrate to flocculate and remove impurities, decoloring and removing impurities by using D101 nonpolar macroporous adsorption resin, filtering and concentrating the treated solution, adjusting the pH value to be neutral, heating and stirring the solution at 70 ℃ and adding alkaline copper carbonate to obtain a purple precipitate, dissolving the purple precipitate by using 1 mo/L sulfuric acid to obtain L-copper sulfate mixed solution, removing L-copper sulfate mixed solution to remove copper sulfate, removing the copper sulfate by using anhydrous ethanol, introducing excessive sulfurated hydrogen into the L-copper sulfate mixed solution to remove copper ions, adding a proper amount of barium hydroxide solution to precipitate sulfate ions, performing suction filtration, concentration, vacuum drying and recrystallization by using anhydrous ethanol to obtain 0.72g of white needle-shaped crystals, namely the camellia chrysantha needle-shaped tea with L-99.99% purity.
(3) The oral preparation is prepared by weighing raw materials according to a certain proportion, L parts of golden camellia, 20 parts of theanine, 50 parts of filler (microcrystalline cellulose/pregelatinized starch is 1:1), 2 parts of lubricant (magnesium stearate), 2 parts of disintegrant (sodium carboxymethyl starch), 1.5 parts of flavoring agent (citric acid), 15 parts of adhesive (corn starch slurry) and 15 parts of sweetening agent (xylitol).
Adding a proper amount of water and sodium carboxymethyl starch into camellia nitidissima L-theanine, stirring at 55 ℃, adding citric acid, uniformly mixing, adding into corn starch slurry in a spraying manner, adding microcrystalline cellulose, namely pregelatinized starch 1:1, magnesium stearate and xylitol, fully mixing uniformly, pressing in a rotary tablet press, and drying in vacuum at 40 ℃ for 2 hours to obtain the camellia nitidissima L-theanine oral preparation with the diameter of 8mm and the weight of 230 mg.
Example 2
(1) The golden camellia pretreatment comprises the steps of selecting golden camellia flowers, preferably selecting the flowers according to Chinese pharmacopoeia (2015), cleaning, drying, crushing into powder, sieving by using a 20-mesh sieve to obtain sieved golden camellia powder, and obtaining small-petal golden camellia (Camelliapauvipitala J.Y, L iang et Z.M.Su).
(2) L-theanine is extracted by weighing 150g of camellia chrysantha tea powder, extracting the camellia chrysantha tea powder for 3.5 hours by using 6 times of 65 ℃ water, filtering, adjusting the pH value of the filtrate to 3.5 by using hydrochloric acid, adding 1% chitosan solution into the filtrate for flocculation and impurity removal, decoloring and impurity removal by using HPD-100 nonpolar macroporous adsorption resin, filtering and concentrating the treated solution, adjusting the pH value to be neutral, heating and stirring the solution at 72 ℃ and adding alkaline copper carbonate to obtain purple precipitate, dissolving the purple precipitate by using 1 mo/L sulfuric acid to obtain L-copper sulfate mixed solution, removing the L-copper sulfate mixed solution for copper sulfate removal, removing excessive copper sulfide ions from the L-copper sulfate mixed solution, adding a proper amount of barium hydroxide solution to precipitate sulfate ions, performing filtration, concentrating, performing vacuum drying, and performing recrystallization by using absolute ethanol to obtain 1.08g of white needle crystals, namely the camellia chrysantha needle crystal with high purity of L-99.99.0.
(3) The oral preparation is prepared by weighing raw materials according to a certain proportion, L parts of golden camellia, 25 parts of theanine, 50 parts of filler (microcrystalline cellulose/pregelatinized starch is 1:1), 1.25 parts of lubricant (polyethylene glycol-4000), 2 parts of disintegrant (soluble starch), 1.6 parts of flavoring agent (citric acid), 18 parts of adhesive (Arabic gum) and 16 parts of sweetening agent (mannitol).
Adding a proper amount of water and soluble starch into camellia chrysantha L-theanine, stirring at 60 ℃, adding citric acid, uniformly mixing, adding the mixture into Arabic gum in a spraying mode, adding microcrystalline cellulose, namely pregelatinized starch, 1:1, polyethylene glycol-4000 and mannitol, fully and uniformly mixing, putting the mixture into a rotary tablet press for pressing, and performing vacuum drying at 45 ℃ for 2.5 hours to obtain the camellia chrysantha L-theanine oral preparation with the size of 14mm 9mm and the weight of 550 mg.
The following experiments prove the efficacy of the Camellia nitidissima L-theanine oral preparation of example 1 and example 2 in resisting novel coronavirus.
(1) Designing primers to obtain a first generation recombinant virus: the RNA of the novel coronavirus COVID-19 is taken as a template, cDNA is synthesized by reverse transcriptase, and the COVID-19S, M, E gene is obtained by PCR technology by taking the cDNA as the template. And constructing pMD-18T recombinant plasmids of the three genes, and identifying. And further constructing pFastBac of the three genesTMThe Dual recombinant plasmid is identified by PCR, double digestion and sequencing. Will pFastBacTMAnd respectively transforming the Dual recombinant plasmids into DH10Bac competent cells, carrying out shake culture for 12-16 h, and carrying out PCR detection. Selecting positive bacterial colonies, amplifying bacteria, extracting Bacmid DNA, obtaining three recombinant rBacmid DNAs, respectively transfecting Sf9 cells with the three recombinant rBacmid DNAs, and harvesting supernate, namely the first-generation recombinant virus.
(2) Obtaining second and third generation recombinant viruses: sf9 cells were infected with 100. mu.l of the first generation recombinant virus, and left at 28 ℃ for 2h, during which the flask was gently shaken to allow the virus to uniformly adsorb the cells. The supernatant was removed, 2ml of complete medium was added, and after culturing at 28 ℃ for 72 hours, the supernatant was collected to obtain a second generation recombinant virus. And (4) continuously passaging the harvested viruses according to the method to obtain third-generation recombinant viruses. Three recombinant baculoviruses were designated rB-S, rB-M, rB-E, respectively, and plaque purification and plaque counting were performed.
(3) Infecting Sf9 cells with purified virus, culturing, collecting supernatant and cells respectively, detecting the expression of recombinant protein by Western-blotting, hemagglutination test and indirect immunofluorescence test, infecting Sf9 cells with three purified recombinant baculovirus rB-S, rB-M or rB-S, rB-M, rB-E together, culturing for about 5 days in a 28 ℃ incubator, collecting infected cells, blowing off adherent cells with PBS, washing for three times, crushing by ultrasonic waves, centrifuging for 10min at 4 ℃, 12,000g, taking supernatant, ultracentrifuging by sucrose density gradient, purifying COVID-19V L P, identifying constituent proteins of V L Ps by Western-blotting, and observing the form of V L Ps by a transmission electron microscope.
(4) Adding Camellia Chysantha L-theanine oral preparation, dissolving purified COVID-19 virus-like particles (V L Ps) in PBS solution as virus stock solution, and performing gradient COVID-19 dilution virus solution (10)-1、10-2、10-3.....10-9) Preparation, followed by viral inoculation (37 ℃, 5% CO)2Incubator), discarding growth liquid, washing with PBS, adding 10PFU/ml virus solution 100 μ l (PBS containing l% bovine serum albumin therein) and adsorbing at 4 deg.C for 1h, washing adsorbed cells with PBS, adding 0.5-3ml of PBS dispersion of Camellia chrysantha L-theanine oral preparation prepared in example 1 and example 2 (in this example, the parameters of example 1), and adding 0.01-0.35mg/ml of Camellia chrysantha L-theanine oral preparation at 37 deg.C and 5% CO2Culturing in an incubator for 8-72h, collecting culture solution of different periods of time, washing dead cells by PBS, measuring live cells by MTT (thiazole blue) colorimetry, measuring virus propagation amount by Plaque Forming Unit (PFU), observing cytopathic effect (cytopathic effect) observed by microscope of different periods of time (8h, 10h, 18h,24h,36h,48h and 72h) until the virus continues to act by antiviral products and the produced CPE does not progress any more, setting a blank control group (golden camellia L-theanine oral liquid is replaced by PBS liquid with the same volume) under the same condition, recording detailed anti-COVID-19 virus detailed data of different golden camellia L-theanine oral liquids, incubating the COVID-19 virus at 37 ℃ according to the method of the invention, and after 10h, the virus PFU reachesThe research data show that the golden camellia L-theanine oral agent has no obvious effect of inhibiting the COVID-19 virus within the concentration range of 0.01-0.05mg/ml, the golden camellia L-theanine oral agent has obvious effect of inhibiting the COVID-19 virus within the concentration range of 0.05-0.35mg/ml and has the best effect of resisting the COVID-19 virus at the concentration of 0.21mg/ml, and the data show that the COVID-19 virus titer of a blank control group is 17.33 × 104PFU/ml, while the COVID-19 virus titer observations were 12.19 × 10mg/ml, respectively, when the concentration of Camellia Chysantha L-theanine oral dosage was 0.06mg/ml, 0.10mg/ml, 0.15mg/ml, 0.21mg/ml, and 0.30mg/ml, respectively4PFU/ml、7.34×104PFU/ml、 1.62×104PFU/ml、0.83×104PFU/ml and 0.96 × 104The effect of all experimental groups on the COVID-19 virus is obviously better than that of a blank control group, wherein under the condition of 0.21mg/ml optimal concentration, the COVID-19 virus PFU value of the experimental group added with the golden camellia L-theanine oral agent is only about 4.8 percent of that of the blank control group, and the COVID-19 virus activity is greatly reduced.
Compared with the prior art, the invention finds that L-theanine extracted from golden camellia can improve the immunity of a human body and can effectively kill novel coronavirus, so that the invention takes high-purity L-theanine extracted from golden camellia as a main antiviral active ingredient, and prepares an oral preparation by compounding auxiliary materials such as a filler, a lubricant, a disintegrant, a flavoring agent, an adhesive, a sweetening agent and the like, thereby providing a new formula for preventing novel coronavirus pneumonia.
The present invention is not limited to the above-described embodiments, and various modifications and variations of the present invention are intended to be included within the scope of the claims and the equivalent technology of the present invention if they do not depart from the spirit and scope of the present invention.
Claims (10)
1. The golden camellia L-theanine oral preparation for preventing the novel coronavirus pneumonia is characterized by comprising, by mass, 15-30 parts of golden camellia L-theanine, 45-65 parts of a filler, 1-2.5 parts of a lubricant, 1-2.5 parts of a disintegrant, 1-3 parts of a flavoring agent, 10-30 parts of an adhesive, 10-30 parts of a sweetening agent and the balance of water.
2. The Camellia chrysantha L-theanine oral preparation for preventing novel coronavirus pneumonia according to claim 1, wherein the disintegrating agent is any one of sodium carboxymethyl starch, soluble starch and crospovidone, and the sweetening agent is any one of xylitol and mannitol.
3. The Camellia nitidissima L-theanine oral preparation for preventing novel coronavirus pneumonia according to claim 2, wherein the filler is microcrystalline cellulose, pregelatinized starch is 1:1, or lactose, and the lubricant is magnesium stearate or polyethylene glycol-4000.
4. The Camellia chrysantha L-theanine oral preparation for preventing novel coronavirus pneumonia according to claim 3, wherein the binding agent is any one of acacia gum and corn starch slurry, and the flavoring agent is citric acid.
5. A preparation method of golden camellia L-theanine oral preparation for preventing novel coronavirus pneumonia is characterized by comprising the following steps:
(1) preprocessing golden camellia: selecting leaves or flowers of the golden camellia, cleaning, drying, crushing and sieving to obtain golden camellia tea powder;
(2) the method comprises the steps of (1) extracting L-theanine, weighing camellia chrysantha tea powder, extracting with water at the temperature of 40-80 ℃ for 2-5 hours, filtering, adjusting the pH value of the filtrate to 3.5, adding a chitosan solution into the filtrate for flocculation and impurity removal, decoloring and impurity removal with a nonpolar macroporous adsorption resin, filtering and concentrating the treated solution, adjusting the pH value to be neutral, heating and stirring at the temperature of 60-80 ℃, adding alkaline copper carbonate to obtain a purple precipitate, dissolving the purple precipitate with sulfuric acid to obtain a L-copper sulfate mixed solution, removing the L-copper sulfate mixed solution, removing copper sulfate, performing suction filtration, concentration, vacuum drying and recrystallization to obtain L-theanine;
(3) the preparation method comprises the steps of weighing the camellia chrysantha L-theanine obtained in the step (2), adding a proper amount of water and a disintegrating agent, stirring at 50-60 ℃, adding citric acid, uniformly mixing, adding into an adhesive in a spraying mode, adding a filling agent, a lubricating agent and a sweetening agent, fully mixing, and drying in vacuum to obtain the camellia chrysantha L-theanine oral preparation.
6. The preparation method of the Camellia chrysantha L-theanine oral preparation for preventing the novel coronavirus pneumonia according to claim 5, wherein the preparation method further comprises a compression step after the step (3), and the Camellia chrysantha L-theanine oral preparation obtained in the step (3) is put into a rotary tablet press and compressed into a buccal tablet.
7. The preparation method of the camellia chrysantha L-theanine oral agent for preventing the novel coronavirus pneumonia according to claim 5, wherein the raw materials in the step (3) comprise, by mass, 15-30 parts of camellia chrysantha L-theanine, 45-65 parts of a filler, 1-2.5 parts of a lubricant, 1-2.5 parts of a disintegrant, 1-3 parts of a flavoring agent, 10-30 parts of a binder, 10-30 parts of a sweetening agent and the balance of water, wherein the disintegrant is any one of sodium carboxymethyl starch, soluble starch and crospovidone, the sweetening agent is any one of xylitol and mannitol, the filler is microcrystalline cellulose, namely pregelatinized starch 1:1 or lactose, the lubricant is any one of magnesium stearate and polyethylene glycol-4000, the binder is any one of acacia and corn starch slurry, and the flavoring agent is citric acid.
8. The method for preparing Camellia nitidissima L-theanine oral preparation for preventing pneumonia of novel coronavirus according to claim 5, wherein in the step (3), the step of removing copper sulfate comprises introducing excessive hydrogen sulfide gas into L-copper theanine sulfate mixed solution to remove copper ions, and adding appropriate amount of barium hydroxide solution to precipitate sulfate ions.
9. The method for preparing Camellia nitidissima L-theanine oral preparation for preventing novel coronavirus pneumonia according to claim 5, wherein in the step (2), the concentration of chitosan solution is 1%, and the nonpolar macroporous resin can be any one of BS-55, BS-65, BS-80, D101, H103, X-5, DM11, HPD-100, D1400, D3250, HP-20, ADS-5 and ADS-8.
10. The application of the camellia chrysantha L-theanine oral preparation for preventing the novel coronavirus pneumonia according to any one of claims 1 to 9, wherein the camellia chrysantha L-theanine oral preparation is applied to preventing the novel coronavirus pneumonia.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010238228.XA CN111437245A (en) | 2020-03-30 | 2020-03-30 | Camellia chrysantha L-theanine oral preparation for preventing novel coronavirus pneumonia and preparation method and application thereof |
| GB2104082.9A GB2594792B (en) | 2020-03-30 | 2021-03-24 | Oral Preparation for Preventing the Novel Coronavirus and Preparation Method and Application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010238228.XA CN111437245A (en) | 2020-03-30 | 2020-03-30 | Camellia chrysantha L-theanine oral preparation for preventing novel coronavirus pneumonia and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111437245A true CN111437245A (en) | 2020-07-24 |
Family
ID=71649306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010238228.XA Pending CN111437245A (en) | 2020-03-30 | 2020-03-30 | Camellia chrysantha L-theanine oral preparation for preventing novel coronavirus pneumonia and preparation method and application thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN111437245A (en) |
| GB (1) | GB2594792B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111991414A (en) * | 2020-07-30 | 2020-11-27 | 福建美拉得康生物制药有限公司 | Application of beta-chitosamine in preventing and treating new coronary pneumonia virus infection |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050090511A1 (en) * | 2002-02-18 | 2005-04-28 | Ajinomoto Co., Inc. | Novel method of preventing infectious diseases |
| WO2005063267A1 (en) * | 2003-12-31 | 2005-07-14 | Beijing Kexin Bicheng Medical Technology Development Co., Ltd. | The oral disintegratable tablet of ginkgo leaves |
| CN102525976A (en) * | 2011-12-14 | 2012-07-04 | 天津药物研究院药业有限责任公司 | Method for preparing strontium ranelate orally disintegrating tablets with fluidized bed |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8465782B2 (en) * | 2006-09-21 | 2013-06-18 | Immune Guard, LLC | Methods and materials for reducing risk of cold and/or flu |
-
2020
- 2020-03-30 CN CN202010238228.XA patent/CN111437245A/en active Pending
-
2021
- 2021-03-24 GB GB2104082.9A patent/GB2594792B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050090511A1 (en) * | 2002-02-18 | 2005-04-28 | Ajinomoto Co., Inc. | Novel method of preventing infectious diseases |
| WO2005063267A1 (en) * | 2003-12-31 | 2005-07-14 | Beijing Kexin Bicheng Medical Technology Development Co., Ltd. | The oral disintegratable tablet of ginkgo leaves |
| CN102525976A (en) * | 2011-12-14 | 2012-07-04 | 天津药物研究院药业有限责任公司 | Method for preparing strontium ranelate orally disintegrating tablets with fluidized bed |
Non-Patent Citations (3)
| Title |
|---|
| 段鹏飞等: ""金花茶的花叶保健功效及超微粉制备技术的应用"", 《中国野生植物资源》 * |
| 袁华等: "离子沉淀法提取茶氨酸工艺研究", 《精细石油化工进展》 * |
| 金慰群: "给免疫系统补充营养，助力防控疫情", 《祝您健康》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111991414A (en) * | 2020-07-30 | 2020-11-27 | 福建美拉得康生物制药有限公司 | Application of beta-chitosamine in preventing and treating new coronary pneumonia virus infection |
| CN111991414B (en) * | 2020-07-30 | 2023-09-01 | 福建美拉得康生物制药有限公司 | Application of beta-chitosamine in preparing medicament for preventing and treating new coronapneumovirus infection |
Also Published As
| Publication number | Publication date |
|---|---|
| GB202104082D0 (en) | 2021-05-05 |
| GB2594792B (en) | 2023-09-27 |
| GB2594792A (en) | 2021-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111450100A (en) | Camellia nitidissima caffeine and chlorogenic acid composition for resisting novel coronavirus as well as preparation method and application of camellia nitidissima caffeine and chlorogenic acid composition | |
| KR20220156605A (en) | Application of Traditional Chinese Medicine Compositions in Preparation of Drugs for Treatment or Prevention of Coronavirus Infection | |
| CN111437245A (en) | Camellia chrysantha L-theanine oral preparation for preventing novel coronavirus pneumonia and preparation method and application thereof | |
| CN101822818B (en) | Composition of Chinese yam polysaccharide and Chinese yam protein and application thereof | |
| CN101747307A (en) | Glycyrrhizic acid removal glycyrrhiza flavonoid and medicament composition thereof | |
| CN102895294A (en) | Astragalus mongholicus injection and preparation method thereof | |
| CN112691138B (en) | Preparation method of mulberry resource extract with in-vitro inhibitory activity on African swine fever virus | |
| CN110801016A (en) | Prebiotics polypeptide composite probiotics for relaxing bowel and promoting digestion and absorption and preparation method thereof | |
| KR20220140801A (en) | Application of Chinese Medicine Compositions in Manufacturing Drugs for Treatment or Prevention of Coronavirus Infection | |
| KR20220156604A (en) | Application of Traditional Chinese Medicine Compositions in Preparation of Drugs for Treatment or Prevention of Coronavirus Infection | |
| CN1778824A (en) | Multiple homogeneous tremella polysaccharide, its extraction and medicinal composition with this compound as active components | |
| CN107753823B (en) | Traditional Chinese medicine composition for treating or preventing hand-foot-and-mouth disease | |
| CN110144015B (en) | Method for synchronously extracting and purifying ganoderan, ganoderma triterpenic acid and amino acid | |
| AU2021103579A4 (en) | Camellia nitidissima C.W.Chi Caffeine and Chlorogenic acid composition for anti-SARS-CoV-2 and preparation method and application thereof | |
| CN113100320A (en) | Walnut oligopeptide candy with function of relieving sub-health fatigue and preparation method thereof | |
| JP2017160180A (en) | Antiviral agent and antiviral food | |
| JP2004277414A (en) | Estrogenic active substance derived from edible mushroom | |
| CN110123921B (en) | Preparation method of banana leaf extract and application of banana leaf extract in resisting dengue fever virus | |
| KR20200035099A (en) | Cyanobacteria extract, preparation method thereof and use thereof | |
| CN111743935A (en) | Traditional Chinese medicine composition for preventing and treating dengue fever virus and preparation method thereof | |
| CN110448623B (en) | Preparation method of banana leaf extract and application of banana leaf extract in resisting chikungunya virus | |
| TW442496B (en) | Processing and applications of fungal mycelia | |
| KR101543720B1 (en) | A composition comprising the ivy leaf extract and the compound isolated therefrom for preventing and treating enterovirus-involved diseases | |
| CN110812415B (en) | Preparation method of heart-benefiting and mind-tranquilizing composition for improving sleep | |
| CN109106825B (en) | Antiviral Chinese medicinal composition and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200724 |
|
| RJ01 | Rejection of invention patent application after publication |